MoonLake Immunotherapeutics
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-227.3M | $-118.9M | $-36.0M | $-50.0M | $-4.5M |
| Depreciation & Amortization | $2.6M | $1.4M | $370.0K | $164.8K | — |
| Depreciation | — | — | $13.2K | $12.4K | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $12.9M | $7.3M | $7.1M | $9.7M | — |
| Net Cash from Operating Activities | $-196.0M | $-116.6M | $-42.8M | $-55.9M | $-611.1K |
| Investing Activities | |||||
| Capital Expenditures | $35.0K | $520.0K | $284.0K | $16.0K | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $203.0M | $-205.6M | $-25.2M | $-32.3M | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | $50 | $0 | $0 | — |
| Net Cash from Financing Activities | $146.0M | $51.3M | $479.7M | $119.7M | $-58.1K |
| Net Change in Cash | $154.1M | $-270.7M | $411.7M | $31.5M | $-669.1K |
| Free Cash Flow | $-196.0M | $-117.1M | $-43.1M | $-55.9M | — |